Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GERN

Geron

GERN Lead: Approved 4 Biotech Distilled articles ↓ 20 filings & releases ↓ Cash $69.2M (Sep 30, 2026) ↓ 4 verdicts ↓ 2 timing quotes ↓
Oncology Nucleic Acid

Market cap $638M 644.2M shares (10-Q, Oct 30, 2026) × $0.990 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. RYTELO EU LR-MDS corporate updateby end of 2026RYTELO EU LR-MDS corporate update, by end of 2026, routine
  2. EU contracted field force corporate2027EU contracted field force corporate, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Capital (as filed)

Cash
$69.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
$10.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$339M cash per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Geron, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-13 Watch Geron Corporation (GERN) — Scientific Deep Dive for RYTELO® (imetelstat) and Pipeline Products Validated telomerase franchise with real revenue floor and near-term MF survival readout, but disappointing launch, expensive levered balance sheet, and valuation already pricing the MF option keep it off the buy list until IMpactMF interim.
  2. 2026-08-06 Speculative buy speculative UPDATE: Geron Corporation (GERN) - The Ramp Is Real, The Break-Even Isn't Commercial floor has firmed enough (three quarters of demand growth, reiterated guide, $326.9M cash, no forced raise) that downside on an IMpactMF miss is less severe, justifying a small binary-sized speculative position ahead of the 2H 2026 interim.
  3. 2026-10-29 Avoid UPDATE: Geron Corporation (GERN) - The Fulcrum Broke the Wrong Way IMpactMF futility stop removes the myelofibrosis survival option that carried the entire upside case, leaving only a levered, second-line MDS business with no near-term catalyst to re-rate the stock.
  4. 2026-11-05 Watch UPDATE: Geron Corporation (GERN) - The Floor Holds Q3 delivered the conditions set for revisiting the name — growing RYTELO ramp, first net income, positive operating cash, and lower opex guidance — but no near-term catalyst, costly EU launch, and live securities litigation keep it off the buy list.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)